Sunshine Biopharma Inc (SBFM)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $2.22M
Last updated: Nov 17, 2026 at 4:37 PM ET
Sunshine Biopharma Inc (SBFM) Statistics
Sunshine Biopharma (SBFM) has a market cap of $2.22M. It kept -17.45% of revenue as net income over the last 12 months.
Total Valuation
| Market Cap | $2.22M |
|---|---|
| Latest price (Nov 17, 2026) | $2.54 |
Key Dates
The next earnings report is expected on Apr 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Apr 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 99.22% over 52 weeks and trades 72.51% below its 50-day average.
| Beta (1Y) | 0.74 |
|---|---|
| 52-Week Change | -99.22% |
| 1-Month Change | -47.48% |
| 3-Month Change | -89.15% |
| 6-Month Change | -97.11% |
| 5-Year Change | -99.99% |
| 10-Year Change | -99.99% |
| Total Return (1Y) | -99.22% |
| Total Return (3Y CAGR) | -97.11% |
| Total Return (5Y CAGR) | -84.05% |
| Return vs SPY (1Y) | -110.71% |
| Max Drawdown (1Y) | -99.17% |
| Max Drawdown (3Y) | -100.00% |
| Sharpe Ratio (1Y) | -2.96 |
| Correlation with SPY (1Y) | 0.06 |
| 50-Day Average | $9.24 |
| 200-Day Average | $94.32 |
| 52-Week Range | $2.53 to $464.00 |
| RSI (14 Days) | 27.9 |
| Average Volume (20 Days) | 389.83K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.47x current liabilities.
| Current Ratio | 6.47x |
|---|---|
| Quick Ratio | 4.03x |
Returns and Efficiency
Return on equity is -21.56% and return on assets is -18.23% over the last 12 months.
| Return on Equity (ROE) | -21.56% |
|---|---|
| Return on Assets (ROA) | -18.23% |
| ROIC (5Y Average) | -27.06% |
| Asset Turnover | 1.08x |
| Inventory Turnover | 2.07x |
| Receivables Turnover | 8.92x |
| Cash Conversion Cycle | 149 days |
Scores
SBFM has an Altman Z-Score of -1.82, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.82 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $35.37M over the last 12 months is down 5.23% from the 12 months before.
| Revenue | $35.37M |
|---|---|
| Revenue Growth (YoY) | -5.23% |
| Gross Profit | $10.74M |
| Operating Income | -$6.09M |
| Pretax Income | -$5.83M |
| Net Income | -$6.17M |
| Reported EPS (TTM) | -$9.31 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.58% of the $33.86M in total assets.
| Cash and Equivalents | $14.62M |
|---|---|
| Working Capital | $26.21M |
| Shareholder Equity | $28.64M |
| Book Value Per Share | $121.65 |
| Tangible Book Value | $26.74M |
| Tangible Book Per Share | $113.60 |
| Total Assets | $33.86M |
| Total Liabilities | $5.22M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $21.22K of capital spending, operating cash flow left -$5.36M of free cash flow.
| Operating Cash Flow | -$5.33M |
|---|---|
| Capital Expenditures | $21.22K |
| Free Cash Flow | -$5.36M |
| FCF Per Share | -$7.04 |
| Depreciation and Amortization | $349.58K |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -17.21%.
| Gross Margin | 30.36% |
|---|---|
| Operating Margin | -17.21% |
| Pretax Margin | -16.48% |
| Net Margin | -17.45% |
| Gross Margin (5Y Average) | 37.28% |
Growth
Revenue grew 102.91% a year over 3 years.
| Revenue Growth (3Y CAGR) | +102.91% |
|---|---|
| Revenue Growth (5Y CAGR) | +247.73% |
Dividends and Yields
SBFM does not pay a dividend. Its free cash flow yield is -895.98%.
| FCF Yield | -895.98% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-20 reverse split on Oct 26, 2026.
| Last Split Date | Oct 26, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:20 |
Analyst Forecast
Consensus estimates put revenue growth at 11.33% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.33% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SBFM
What is SBFM's market cap?
Sunshine Biopharma has a market cap of $2.22M.
How many shares of SBFM are outstanding?
Sunshine Biopharma has 235.31K shares outstanding.
Does SBFM pay a dividend?
No. Sunshine Biopharma does not pay a dividend.
SBFM pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors